Asish Xavier

EpiBiologics is advancing bispecific antibodies that selectively degrade membrane and soluble proteins, including GPCRs. Our EpiTAC platform leverages a novel atlas of tissue-selective degrader receptors to drive deep and durable efficacy. The company was founded in 2022 based on pioneering work from Dr. Jim Wells at UCSF. Headquartered in the SF Bay Area, EpiBiologics is backed by leading healthcare investors and building a clinical stage pipeline for oncology and immunology. For more information, please visit epibiologics.com and follow us on LinkedIn.

Link Cell Therapies was launched by Stanford founders Robbie Majzner and Crystal Mackall in partnership with investors Samsara BioCapital and Sheatree Capital. The company is developing a best-in-class logic-gate technology to spur a new generation of cell therapies for patients with solid tumors. Link’s “AND” gates require two cancer-associated targets for a CAR T cell to attack cancer cells, thereby providing specificity for killing of tumor cells while sparing healthy tissue. Combined with additional technologies under development, Link will advance a suite of exciting internal therapeutic programs while exploring opportunities for value creation with strategic partners.

Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary “Bright Peak Immunocytokines”, and to other cytokines as “duokines”. The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its "off-the-shelf" feature. Using a pioneering site-specific ADC-like chemical conjugation technology, any therapeutic antibody at any stage of development can be conjugated with Bright Peak’s cytokine payloads of choice, eliminating the current complexities of antibody engineering and cell line development. Bright Peak’s team works with a passion for innovation and bold science. We are an international research-driven organization dedicated to discovering and developing cutting edge therapies that will make a difference in the lives of patients. We aim to create a vibrant and international corporate culture and are currently hiring in our Basel, Switzerland and Southern California locations.

Capstan Therapeutics is now part of AbbVie. AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance peoples lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. For more information about AbbVie, please visit us at www.abbvie.com. Follow AbbVie on LinkedIn for future updates. 

At Rondo Therapeutics we believe that our success as a company starts with building a culture based on teamwork, trust, career growth, and a sense of fun. We develop innovative bispecific antibody therapies, specifically targeting unmet needs in solid tumors. Our bispecific antibodies are designed with broad therapeutic windows, sparing healthy tissue while eradicating tumors. If you are a fearless scientist driven to make new discoveries and you value collaboration, respect, and working in a team environment, then we want to hear from you! Join us in our mission to create novel molecules that bring new hope to cancer patients while advancing your career in a merit-based culture.

Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. In April 2023, Pipeline announced that it entered into a global license and development agreement with Janssen Pharmaceutica NV (Janssen) for its lead program, PIPE-307, a highly selective M1 antagonist, in central nervous system disorders. The Company’s second program, PIPE-791, an LPA1 receptor antagonist, has received FDA clearance of its IND and is advancing into Phase 1 testing.

We now know that immune cells – not only in the body’s periphery but especially in the brain – can produce autoantibodies that cause severe neurological and psychiatric diseases. Founded to explore the latest discoveries in autoimmune neuropsychiatry, Arialys Therapeutics is developing new precision medicines to specifically block pathogenic autoantibodies in the brain and meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease.

SonoThera is developing ultrasound-mediated nonviral genetic therapies.

Datavant makes the world’s health data secure, accessible and usable. Datavant is a data platform company for healthcare whose products and solutions enable organizations to move and connect data securely. Through proprietary technology, the world’s most robust healthcare network, and value-added services we protect, connect, and deliver the world’s health data. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 70,000 hospitals and clinics, 70% of the 100 largest health systems, and an ecosystem of 500+ real-world data partners. To learn more about Datavant, visit datavant.com.

Legend Biotech is a global, commercial-stage biotechnology company developing and manufacturing novel therapies. We explore and apply innovative technologies to deliver cutting-edge options for patients around the world. Our corporate headquarters is located in Somerset, NJ, and our manufacturing footprint includes facilities in the United States, China and the Belgium.

Aduro Biotech, Inc. (Nasdaq: ADRO) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies that are designed to harness the body’s natural immune system for the treatment of patients with challenging diseases. Aduro's product candidates in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways are being investigated in cancer, autoimmune and inflammatory diseases. ADU-S100 (MIW815), which potentially activates the intracellular STING receptor for a potent tumor-specific immune response, is being evaluated in patients with cutaneously accessible metastatic solid tumors or lymphomas. BION-1301, a fully blocking monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors, is being evaluated for the treatment of IgA nephropathy. Aduro is collaborating with a number of leading global pharmaceutical companies to help expand and drive its product pipeline.

Nevro is a global medical device company focused on delivering innovation to improve the quality of life for patients suffering from debilitating chronic pain. Through HFX, Nevro brings together enduring technologies, optimized therapies, and individualized patient support, all built on a foundation of proof that results in a comprehensive solution to relieve the burden of pain for more patients. HFX is a comprehensive solution that includes a Senza spinal cord stimulation system and support services for the treatment of chronic pain, including painful diabetic neuropathy when programmed with a frequency of 10 kHz.

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com. Community Guidelines: http://www.jnj.com/social-media-community-guidelines

Five Prime Therapeutics, Inc. (NASDAQ: FPRX) is a publicly traded, clinical-stage biotechnology company focused on discovering and developing innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. Five Prime is committed to innovation and outstanding science to develop effective new drugs for the treatment of severe diseases. We value our culture of openness, collaboration and productivity.

EpiBiologics is advancing bispecific antibodies that selectively degrade membrane and soluble proteins, including GPCRs. Our EpiTAC platform leverages a novel atlas of tissue-selective degrader receptors to drive deep and durable efficacy. The company was founded in 2022 based on pioneering work from Dr. Jim Wells at UCSF. Headquartered in the SF Bay Area, EpiBiologics is backed by leading healthcare investors and building a clinical stage pipeline for oncology and immunology. For more information, please visit epibiologics.com and follow us on LinkedIn.

Link Cell Therapies was launched by Stanford founders Robbie Majzner and Crystal Mackall in partnership with investors Samsara BioCapital and Sheatree Capital. The company is developing a best-in-class logic-gate technology to spur a new generation of cell therapies for patients with solid tumors. Link’s “AND” gates require two cancer-associated targets for a CAR T cell to attack cancer cells, thereby providing specificity for killing of tumor cells while sparing healthy tissue. Combined with additional technologies under development, Link will advance a suite of exciting internal therapeutic programs while exploring opportunities for value creation with strategic partners.

Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary “Bright Peak Immunocytokines”, and to other cytokines as “duokines”. The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its "off-the-shelf" feature. Using a pioneering site-specific ADC-like chemical conjugation technology, any therapeutic antibody at any stage of development can be conjugated with Bright Peak’s cytokine payloads of choice, eliminating the current complexities of antibody engineering and cell line development. Bright Peak’s team works with a passion for innovation and bold science. We are an international research-driven organization dedicated to discovering and developing cutting edge therapies that will make a difference in the lives of patients. We aim to create a vibrant and international corporate culture and are currently hiring in our Basel, Switzerland and Southern California locations.

Capstan Therapeutics is now part of AbbVie. AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance peoples lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. For more information about AbbVie, please visit us at www.abbvie.com. Follow AbbVie on LinkedIn for future updates. 

At Rondo Therapeutics we believe that our success as a company starts with building a culture based on teamwork, trust, career growth, and a sense of fun. We develop innovative bispecific antibody therapies, specifically targeting unmet needs in solid tumors. Our bispecific antibodies are designed with broad therapeutic windows, sparing healthy tissue while eradicating tumors. If you are a fearless scientist driven to make new discoveries and you value collaboration, respect, and working in a team environment, then we want to hear from you! Join us in our mission to create novel molecules that bring new hope to cancer patients while advancing your career in a merit-based culture.